MBio Diagnostics, Inc.

About

MBio Diagnostics, Inc. is a biotechnology company dedicated to developing advanced diagnostic solutions that facilitate rapid disease detection for healthcare providers and laboratories worldwide.Founded in 2009 in Boulder, US, MBio Diagnostics specializes in diagnostic solutions, detecting infectious diseases and other medical conditions. The company has undergone strategic evolution, culminating recently in a Trade Sale in September 2022, where Heska Corporation acquired MBio for USD 38.70 mn. The acquisition is anticipated to finalize in the first half of 2023. The company has successfully completed 11 deals to date.MBio Diagnostics, Inc. specializes in the development and commercialization of advanced diagnostic solutions that cater primarily to the needs of healthcare providers and laboratories. Their core product offerings include a range of diagnostic assays designed to detect infectious diseases and other medical conditions, leveraging technologies to ensure rapid and accurate results. These products are utilized in various clinical settings, including hospitals, outpatient clinics, and reference laboratories, addressing the growing demand for timely disease identification and management. The company serves a diverse client base consisting of healthcare institutions, researchers, and diagnostic laboratories across North America, Europe, and Asia-Pacific markets.The revenue model of MBio Diagnostics, Inc. is structured around direct sales and partnerships with healthcare providers and diagnostic laboratories. Transactions occur primarily through bulk purchasing agreements and service contracts. The company offers a variety of pricing plans tailored to their range of diagnostic assays, ensuring that clients can select options that best fit their operational needs. Their flagship products contribute significantly to revenue through both single-sale transactions and ongoing service agreements, supported by established relationships with healthcare entities.MBio Diagnostics, Inc. aims to expand its product offerings and market presence in the diagnostic sector. The company is developing new products designed to enhance disease detection capabilities, though specific release dates are yet to be announced. Market expansion plans include targeting healthcare systems in emerging markets across Europe and Asia-Pacific by 2025. The recent acquisition by Heska Corporation will facilitate these initiatives, with the USD 38.70 mn raised expected to enhance product development and market entry strategies.